Tyrosine kinase inhibitor (TKI) therapy has significantly improved the survival of patients with chronic phase chronic myeloid leukemia (CML), with a 10-year survival rate of approximately 90%.1 However, one-third of patients continue to experience treatment failure. Therapeutic failure occurs more frequently in patients at higher risk of disease progression and mortality during TKI therapy.
Mattozzi, A., Galli, E., Autore, F., Pansini, I., Chiusolo, P., Colangelo, M., Sica, S., Sora', F., Validation of a New Scoring System for Treatment Failure in CML Patients on Tyrosine Kinase Inhibitors in a Real-World Setting, <<MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES>>, 2026; 18 (1): N/A-N/A. [doi:10.4084/MJHID.2026.013] [https://hdl.handle.net/10807/343797]
Validation of a New Scoring System for Treatment Failure in CML Patients on Tyrosine Kinase Inhibitors in a Real-World Setting
Mattozzi, Andrea;Galli, Eugenio;Autore, Francesco;Pansini, Ilaria;Chiusolo, Patrizia;Colangelo, Maria;Sica, Simona;Sora', Federica
2026
Abstract
Tyrosine kinase inhibitor (TKI) therapy has significantly improved the survival of patients with chronic phase chronic myeloid leukemia (CML), with a 10-year survival rate of approximately 90%.1 However, one-third of patients continue to experience treatment failure. Therapeutic failure occurs more frequently in patients at higher risk of disease progression and mortality during TKI therapy.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Mattozzi+PDF.pdf
accesso aperto
Tipologia file ?:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
373.64 kB
Formato
Adobe PDF
|
373.64 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
